Lê Đức Lợi @leducloidn

The next era of ownership is opening. You in or not?

Your points finally have a market on @arbitrum Check, track and trade points across any integrated project and chain.

Get crypto rewards for travelling on @travalacom ✈️ The AVA Smart Program is the leading web3 travel loyalty program 🌟 Perks include: 🌍 Crypto Rewards 🛍️ Discounts 🎁 $AVA Bonuses + much more Stop collecting points & take ownership of your rewards 🔓 Join for FREE today 👇

Good

OneAsset @OneAsset_io

5 days ago

The next era of ownership is opening. You in or not?

133 90 76 1K 1

Scaling AI shouldn’t be expensive or centralized With Hyra Zone Builders can tap into a global pool of decentralized GPUs with: ⚡ Diverse GPU options (A40, 4090, A100… and more) ⚡ High-bandwidth performance for heavy AI workloads ⚡ 30–70% lower cost compared to AWS / GCP ⚡ Instant access — no long queues, no capacity limits ⚡ A decentralized network powered by real node operators Whether you're training models, running inference, or testing production workloads, Hyra Zone gives you enterprise-grade compute delivered through a community-powered ecosystem. Why overpay for centralized cloud when you can scale smarter? 👉 Train your AI with optimal cost, maximum speed, and truly open infrastructure. #HyraZone #HyraNetwork #AIInfra #GPU #DePIN #AIRevolution

🔥HyraZone is LIVE NOW🔥 Supercharge your AI projects with HyraZone: - Decentralized GPU cloud - Rent powerful GPUs at 30–70% lower costs than AWS or GCP - Ultra-fast bandwidth and flexible hourly pricing Explore & let’s power the AI future together NOW 👉 hyrazone.com/en

The GPU shortage isn’t just a hardware issue but an infrastructure opportunity.💻🖥 Startups, AI builders, and researchers are hungry for scalable compute that isn’t locked behind Big Tech paywalls. Hyra Network is bridging that gap through decentralized infra. By tapping into idle devices and high-end GPU nodes, Hyra Network is: ✅ Lowering compute costs ✅ Enabling faster AI training ✅ Empowering builders to own the infra they rely on It's DePIN in motion, try now: hyra.network

🚀 Hyra AI: 2,500,000+ Connected Devices From smartphones and tablets to IoT and edge GPUs, our growing network proves: Idle compute isn’t idle anymore. Every connected device contributes to powering real-time inference, edge learning, and decentralized AI applications across 205 countries. ⚙️ Scalable ⚡️ On-demand 🌍 Open to all Next stop? 10 million???

Every clinical trial is a controlled experiment. That is its strength. It is also its limit. Trials recruit narrow populations: younger, healthier patients with fewer comorbidities and fewer medications than the people who will eventually use the drug. This is not a flaw in design. It is a structural consequence of how controlled evidence works. A drug that performs well in that population gets approved. The patient who receives it in clinical practice is often someone the trial never tested. This gap has a name: real world evidence. Most of the industry measures it only after approval, too late to inform the decisions that mattered most. Validating therapies in populations that more closely reflect real patients before approval can change what gets approved and who actually benefits from it.

@NOWChainX Wonderful

The longer I spend building, the more I realize that adoption is rarely a technology problem. Most of the time, it's a trust problem. People don't adopt something because it's technically impressive. They adopt it when they understand it. When they trust it. When they see value in it. Technology opens the door. Trust is what gets people to walk through it. ⚡

@LifeNetwork_AI Wonderful

One thing I've learned building in Web3 is that communities don't form overnight. People often see a large community and assume it was always there. The reality is usually much different. It starts with a handful of people who believe in an idea before there is proof. They show up early. They ask questions. They provide feedback. They stay when things are still uncertain. Over time, those early conversations become relationships. Those relationships become a community. And eventually that community becomes one of the most valuable assets any ecosystem can have. Technology matters. Infrastructure matters. But communities are what bring them to life. ⚡ #NOWChain

A drug spends years in trials, then decades in the real world. The real world generates far more evidence about how it actually performs than any trial. That evidence rarely goes anywhere. Which patients respond. What side effects emerge. How it behaves across populations the trial never tested. The most valuable evidence in the entire lifecycle — and it almost never flows back into what gets discovered or trialed next. Every new program starts from the same incomplete picture as the last. AI can generate more candidates than ever. But a pipeline that can’t learn from its own history won’t produce a different outcome. The missing infrastructure isn’t discovery. It’s the loop back.

In the last 30 years, computing power has increased by a factor of a trillion. Yet developing a new therapy remains one of the slowest, most expensive, and most failure-prone processes in modern science. This is the paradox worth understanding. AI has accelerated target identification. Gene sequencing has collapsed from years to days. Computational modeling can simulate molecular interactions at a scale that was unimaginable a decade ago. Yet the pipeline moves at the same pace. The reason is that technology has made individual stages of the process faster. What it has not changed is the structure of the process itself. Drug development is still sequential. Each stage waits for the one before it. Each program still assembles its own evidence infrastructure from scratch. The handoff between controlled validation and real-world performance still happens after approval. Better tools applied to a fragmented, sequential process produce better science at the same speed. What compresses the timeline is not faster tools inside the existing structure. It is a different structure entirely.

Clinical trials are the most expensive phase of drug development. They are also the phase most likely to fail. Phase I: testing safety in a small group. Phase II: testing efficacy in a larger group. Phase III: confirming results across a broad population. Each phase takes years. Each phase requires recruiting participants who fit narrow eligibility criteria. And each phase validates a drug against a controlled population that rarely reflects the biological diversity of the patients it will eventually serve. This is the fundamental problem with how clinical trials are designed. The evidence is generated in a controlled environment. The drug is deployed in the real world. The gap between those two contexts is where most post-market failures begin. Real-world validation — continuous, population-diverse, outside the trial — is not a supplement to clinical trials. It is what makes the evidence from clinical trials actually predictive.

The wait is over. The Burn-Mint Equilibrium (BME) proposal is going onchain for a vote today, with an upgrade scheduled for March 23rd at 14:00 UTC. BME restores direct utility to $AKT, anchoring token value to real network usage, where every $AKT used for deploying will be burnt. This upgrade also introduces WASM smart contracts to Akash - a foundational step that enables the Core Team to iterate and build faster without full chain coordination. Cast your vote & track the proposal live on Mintscan ↓ mintscan.io/akash/proposal…

Every strong ecosystem starts with people building something others once thought was impossible. A simple idea. A small project. A single builder. Then momentum begins. The future of Web3 won't be defined by chains competing for attention. It will be defined by ecosystems creating opportunities for builders to create, connect, and grow. We're building for those who keep building. ⚡ #NOWChain #Builders #BuildInPublic

There's a difference between using a network and helping shape one. Most people arrive when everything is already built. Builders arrive when nothing is guaranteed. They take risks. They experiment. They create opportunities that didn't exist before. Years later, people only see the outcome. Few remember who helped build the foundation. To everyone building alongside us: The future is created long before it becomes visible. ⚡ #NOWChain #Builders

The hardest part of building isn't technology. It's patience. Patience when growth feels slow. Patience when the vision is larger than the current reality. Patience to keep building while others are waiting for results. Every meaningful ecosystem goes through this stage. The work happens first. Recognition comes later. Keep building. ⚡ #NOWChain #BuildInPublic